Myeloid-derived suppressor cells in immunity and autoimmunity

References

• Liu G, Bi Y, Shen B, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res 2014;74(3):727-37
   PubMed Web of Science ®Google Scholar
• Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2010;12(6):417-30
   Google Scholar
• Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012;41(6-7):614-34
   PubMed Web of Science ®Google Scholar
• Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010;22(2):238-44
   Google Scholar
• Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013;138(2):105-15
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69(4):1553-60
   PubMed Web of Science ®Google Scholar
• Liu G, Bi Y, Wang R, et al. Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells1. J Immunol 2014;192(7):3068-79
   Google Scholar
• Zhang Y, Bi Y, Yang H, et al. mTOR limits the recruitment of CD11b+Gr1+Ly6Chigh myeloid-derived suppressor cells in protecting against murine immunological hepatic injury. J Leukoc Biol 2014
   Google Scholar
• Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70(11):4335-45
   PubMed Web of Science ®Google Scholar
• Gowda M, Godder K, Kmieciak M, et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011;9:170
   PubMed Web of Science ®Google Scholar
• Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009;183(2):937-44
   PubMed Web of Science ®Google Scholar
• Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004;173(6):3844-54
   PubMed Web of Science ®Google Scholar
• Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010;70(9):3526-36
   PubMed Web of Science ®Google Scholar
• Qu P, Du H, Li Y, et al. Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung. J Immunol 2009;182(3):1648-59
   Google Scholar
• Foell D, Wittkowski H, Vogl T, et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81(1):28-37
   PubMed Web of Science ®Google Scholar
• Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205(10):2235-49
   PubMed Web of Science ®Google Scholar
• Farren MR, Carlson LM, Lee KP. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res 2010;46(1-3):165-76
   PubMed Web of Science ®Google Scholar
• Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116(10):2777-90
   PubMed Web of Science ®Google Scholar
• Greifenberg V, Ribechini E, Rossner S, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009;39(10):2865-76
   PubMed Web of Science ®Google Scholar
• Arora M, Poe SL, Oriss TB, et al. TLR4/MyD88-induced CD11b+Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol 2010;3(6):578-93
   Google Scholar
• Zanzinger K, Schellack C, Nausch N, et al. Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology 2009;128(2):185-95
   Google Scholar
• Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006;25(3):323-31
   Google Scholar
• Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008;14(5):408-19
   PubMed Web of Science ®Google Scholar
• Hirai H, Zhang P, Dayaram T, et al. C/EBPbeta is required for ‘emergency’ granulopoiesis. Nat Immunol 2006;7(7):732-9
   PubMed Web of Science ®Google Scholar
• Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2011;32(6):790-802
   Google Scholar
• Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010;32(6):790-802
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Silvera R, Carrio R, et al. Tumor microenvironment profoundly modifies functional status of macrophages: peritoneal and tumor-associated macrophages are two very different subpopulations. Cell Immunol 2010;283(1-2):51-60
   Google Scholar
• Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010;235(1):267-85
   PubMed Web of Science ®Google Scholar
• Olechnowicz SW, Edwards CM. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res 2010;74(6):1625-31
   Google Scholar
• Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7(9):678-89
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12(4):253-68
   PubMed Web of Science ®Google Scholar
• Angelini G, Gardella S, Ardy M, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A 2002;99(3):1491-6
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010;70(1):68-77
   PubMed Web of Science ®Google Scholar
• Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010;116(25):5738-47
   PubMed Web of Science ®Google Scholar
• Bronte V, Serafini P, Mazzoni A, et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003;24(6):302-6
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Zea AH, Culotta KS, et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002;277(24):21123-9
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13(7):828-35
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005;202(7):919-29
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66(2):1123-31
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68(13):5439-49
   PubMed Web of Science ®Google Scholar
• Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70(1):99-108
   PubMed Web of Science ®Google Scholar
• Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012;12(4):239-52
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198(11):1741-52
   PubMed Web of Science ®Google Scholar
• Ko HJ, Lee JM, Kim YJ, et al. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009;182(4):1818-28
   PubMed Web of Science ®Google Scholar
• Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13(2 Pt 2):721s-6s
   PubMed Web of Science ®Google Scholar
• Kmieciak M, Basu D, Payne KK, et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011;187(2):708-17
   PubMed Web of Science ®Google Scholar
• De Santo C, Salio M, Masri SH, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008;118(12):4036-48
   PubMed Web of Science ®Google Scholar
• Li R, Deng F, Fu Y, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys. Pharmacology 2010;85(6):319-27
   Google Scholar
• Sinha P, Clements VK, Bunt SK, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179(2):977-83
   PubMed Web of Science ®Google Scholar
• Mildner A, Mack M, Schmidt H, et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009;132(Pt 9):2487-500
   Google Scholar
• King IL, Dickendesher TL, Segal BM. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009;113(14):3190-7
   PubMed Web of Science ®Google Scholar
• Bowen JL, Olson JK. Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler’s virus-induced demyelinating disease. J Immunol 2009;183(11):6971-80
   Google Scholar
• Gorham JD, Lin JT, Sung JL, et al. Genetic regulation of autoimmune disease: BALB/c background TGF-beta 1-deficient mice develop necroinflammatory IFN-gamma-dependent hepatitis. J Immunol 2001;166(10):6413-22
   Google Scholar
• Gold DP, Schroder K, Powell HC, et al. Nitric oxide and the immunomodulation of experimental allergic encephalomyelitis. Eur J Immunol 1997;27(11):2863-9
   Google Scholar
• Kahn DA, Archer DC, Gold DP, et al. Adjuvant immunotherapy is dependent on inducible nitric oxide synthase. J Exp Med 2001;193(11):1261-8
   Google Scholar
• Cross AH, Ramsbottom MJ, Lyons JA. NOS2 regulates cytokine production and VLA-4 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006;173(1-2):79-86
   Google Scholar
• Olson JK, Girvin AM, Miller SD. Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler’s virus. J Virol 2001;75(20):9780-9
   Google Scholar
• Sander LE, Sackett SD, Dierssen U, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med 2010;207(7):1453-64
   Google Scholar
• Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol 2011;11(7):789-93
   PubMed Web of Science ®Google Scholar
• Cripps JG, Wang J, Maria A, et al. Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology 2010;52(4):1350-9
   PubMed Web of Science ®Google Scholar
• Longhi MS, Mitry RR, Samyn M, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009;50(1):130-42
   Google Scholar
• Westendorf AM, Fleissner D, Deppenmeier S, et al. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells. Gastroenterology 2006;131(2):510-24
   Google Scholar
• Zhou Z, French DL, Ma G, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010;28(3):620-32
   PubMedGoogle Scholar
• Haile LA, von Wasielewski R, Gamrekelashvili J, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008;135(3):871-81
   PubMed Web of Science ®Google Scholar